Answers are grounded in this paper and cite their sources.
a leave-one-out analysis. Compared with ibrutinib and rituximab, zanubrutinib demonstrated significant benefits in terms of both overall response and progression-free survival in patients with previously treated MZL.
No takes yet. Share an insight, caveat, or question.
Thieblemont et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: